Abstract MicroRNAs (miRNAs) are non-coding regulatory RNAs consisting of 20-24 nucleotides. Over 4,500 miRNAs have been identified in humans, and it is known that nearly all human protein-encoding genes can be controlled by miRNAs in both healthy and malignant cells.
Introduction
MicroRNAs (miRNAs) are non-coding regulatory RNAs consisting of 20-24 nucleotides [1] . miRNAs act by controlling the translation of proteins from mRNAs, and by doing so play a crucial role in normal cell differentiation and proliferation [1] . miRNAs were first identified by Ambros and coworkers in the nematode Caenorhabditis elegans (1993), who showed that the miRNA lin-4 plays an important role in cellular differentiation through inhibition of lin-14 expression [2] . Thereafter, Ruvkun's group (2000) identified let-7, another lin-4-like small non-coding RNA, in worms [3] , and Bartel's and Tuschl's labs (2001) independently cloned and identified miRNAs from worms, flies, and humans [4, 5] . At present, over 4,500 miRNAs have been identified in humans, and it is known that nearly all human protein-encoding genes can be controlled by miRNAs in both healthy and malignant cells. Abnormal expression of miRNA is now known to occur in many cancers, including malignant lymphomas (MLs) [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Malignant lymphoma is classified into Hodgkin's or non-Hodgkin's lymphoma. On the basis of normal correspondence lymphoid cells, non-Hodgkin's lymphoma is further classified into B-and T/NK-cell lymphomas. These can also be divided into a number of subtypes; for instance, B-cell lymphoma can be classified into diffuse large B-cell lymphoma, Burkitt's lymphoma, mantle cell lymphoma, follicular lymphoma, MALT (mucosa-associated lymphoid tissue) lymphoma, and other subtypes [15, 16] . These classifications are usually made on the basis of subtypespecific translocation or origin of their normal parts. In B-cell lymphomas, molecular-based classifications of the subtypes have been successfully conducted, leading to the development of understanding of their pathogenesis. Subtype-based miRNA classification has also been successfully conducted in B-cell lymphomas [11] [12] [13] [14] . In T-cell lymphomas, however, attempts at translocation-or molecular-based classification have been unsuccessful to date, and as a result, understanding of molecular-based pathogenesis of T-cell lymphoma has been insufficiently established. This suggests that other classification strategies, such as miRNA expression analysis, may be additionally useful.
miRNA dysregulation may be associated with pathogenesis or disease progression in T-cell lymphoma. Recent studies have revealed the deregulation of key miRNAs and their targets in well-defined T-cell lymphomas, such as anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. In this review, we discuss the association between miRNA and normal T-cell differentiation, summarize recent findings on the roles of miRNA in T-cell lymphoma pathogenesis, and provide perspectives into the use of new candidate drugs for treating tumor entities. Further, we propose some problems confronting miRNA studies against MLs, which remain to be addressed in future studies.
MicroRNA functions in normal T-cell differentiation
Recent studies have shown that several miRNAs are deeply associated with lymphoid development and maturation. Before we describe miRNA functions in T-cell lymphomas, we should begin by outlining miRNA function in normal T-cell differentiation, as dysregulation of miRNAs can induce tumorigenesis in otherwise normal T cells.
T-cell development in the thymus is controlled by a complex but precise signal network. Developmental stages are classified as double-negative (DN), double-positive (DP), and single-positive (SP) with respect to CD4
? and/or CD8 ? T cells. T-cell receptor (TCR) rearrangement occurs during the transition from DN to DP, or from DP to SP. T cells are selected by specificity of antigen specification, which is defined by the TCR variable region.
Chen and coworkers [17] first reported a miRNA association in hematopoiesis. They found that, as miR-181, miR-223, and miR-142s are highly expressed in murine hematopoietic cells, enforced expression of miR-223 and miR-142s led hematopoietic stem cells to mature into the T-cell lineage, while miR-181 expression led to B-cell maturation. These miRNAs are now recognized for their important roles in hematopoiesis. miR-150 also plays a crucial role in lymphoid cell development. Monticelli and coworkers [18] reported that, in a mouse model, although miR-150 expression was not detected in pro T-or B-cells, the expression did appear, and became stronger with lymphocyte maturation. However, in mature T cells, the expression is lower in naïve T cells to T H 1 or T H 2 cells. In addition, CD4
? T helper cells are divided into T H 1, T H 2, T H 17, and T H 22 subsets. Zhou and coworkers [19] also focused on miR-150, which usually shows high expression in spleen and thymus. They demonstrated that miR-150 inhibits pro-B to pre-B development. In other work the same year, Xiao and coworkers [20] reported that miR-150 regulates B-cell maturation by targeting a transcription factor, c-Myb. There is a deep relationship between miR-150 and c-Myb in T-cell development, as c-Myb is highly activated in DN3 (CD44 -/CD25 ? ) and DP or SP, and its activation is necessary for their development [21, 22] . Recently, a novel target of miR-150 during T-cell development has been reported. Using whole-genome miRNA analysis against DP or SP of CD4
? or CD8 ? , Ghisi and coworkers [23] identified several miRNAs that may be associated with the transition from DP to SP. They focused on miR-150, which is highly expressed in the SP phase, and found that miR-150 controls Notch3, and that Notch3 deregulation may induce T-cell malignancies [24] .
Other miRNAs associated with T-cell differentiation include miR-181a and miR-155. Li and coworkers [25] demonstrated that miR-181a is highly expressed in earlier phases of T-cell maturation, such as DN (especially DN3) or DP, and that its expression decreases after the SP phase through the regulation of dual-specificity phosphatase (DUSP) 5/6, which potentially inhibits extracellular signal-regulated kinase (ERK) signaling or a tyrosine phosphatase, SHP-1/2. Neilson and coworkers [26] also reported that miR-181a negatively regulates Bcl2, CD69, or TCR during the DP phase. These reports demonstrate that miR-181a plays crucial roles in T-cell sensitivity and selection. As for miR-155, Thai and coworkers [27] demonstrated that knockdown of miR-155 leads T cells to differentiate into the T H 2 type with up-regulation of IL-4 and down-regulation of interferon-c (IFN-c). At the same time, Rodriguez and coworkers [28] also showed that miR-155 targets c-Maf, which is expressed in T H 2 CD4
? T cells, leading to down-regulation of IL-4. These findings suggest that miR-155 expression regulates T-cell development, especially differentiation into T H 1 CD4 ? T cells.
These studies show that a number of miRNAs are deeply associated with the control of important signaling pathways in T-cell development and maturation. Interestingly, these reports reveal that a single miRNA (e.g., miR-150) potentially possesses diverse functions by regulating various targets in different stage of cell differentiation, suggesting that a miRNA may target the translation of various proteins in different cancer cell lineage, including malignant lymphomas. These reports also suggest that miRNA dysregulations associated with T-cell development may show strong correlations with T-cell malignancies.
miRNA expression analysis against T-cell lymphomas
In the WHO (World Health Organization) classification, T-cell lymphomas are histopathologically heterogeneous and can be classified into *20 subtypes [29] . T-cell lymphomas are subdivided in three major subgroups, (A) cutaneous [mycosis fungoides (MF), Sézary syndrome (SzS), primary cutaneous CD30-positive T-cell lymphoproliferative disorders and primary cutaneous T-cell lymphoma (CTCL), etc.], (B) nodal [peripheral T-cell lymphoma (PTCL), PTCL-not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), and adult T-cell leukemia/lymphoma (ATLL)], and (C) extranodal. With the exception of ALK-positive (ALK ? ) ALCL, subtype-specific translocation has not been observed in T-cell lymphomas. Therefore, the development of molecular-based therapeutic strategies for T-cell lymphoma remains insufficient, particularly when compared with those for B-cell lymphoma.
Other than specific translocations, such as t(2;5) (p23;q35), as seen in ALK ? ALCL, there is no subtypespecific translocation in T-cell lymphomas associated with a known miRNA alteration. Whole-genome miRNA expression analyses of malignant lymphomas are the subject of international research [30] [31] [32] ; however, efforts at unsupervised miRNA expression analysis, including those in various T-cell lymphoma subtypes, remain unsuccessful. Although the aberrant expression of many miRNAs has been identified in T-cell lymphomas, when one compares miRNA expression of tumor samples with normal correspondence cells, there is a poor overlap among differentially expressed miRNAs identified by multiple miRNA platforms. We thus must further validate such findings to examine whether identified miRNAs are in fact functional in the regulation of genes associated with lymphomagenesis. To identify the roles of miRNA deregulation in lymphomagenesis, studies in combination with whole-genome gene expression analysis may be useful. In this vein, Suzuki and coworkers [33] recently developed a novel method for detecting relationships between miRNAs and their candidate targets, which they call GSEA-FAME analysis (GFA). This method was also useful for detecting essential and novel therapeutic targets of unclassified T-cell lymphomas [34] .
In the following sections, we focus on miRNA dysregulation and its function in (a) CTCL (SzS, MF), (b) nodal peripheral T-cell lymphomas [(1) ALCL, (2) ATLL, (3) PTCL-NOS], and (c) extranodal (e.g., NK/T-cell lymphoma, nasal type). Deregulated miRNAs in T/NK-cell lymphomas are summarized in Table 1 .
Subtype-specific miRNA dysregulation in T-cell lymphoma/leukemias CTCL includes several subtypes, such as MF, SzS, cutaneous-ALCL and others. MF follows an indolent clinical course and accounts for nearly 50 % of all primary cutaneous lymphomas [29, 35] , whereas SzS (5 %) shows an [36] [37] [38] [39] [40] . Although to date no specific genomic translocations have been identified in CTCL, it is known that some interleukins (ILs) activate miRNAs via activation of upstream regulators of the JAK (Janus kinase)/STAT (signal transduction and activator of transcription) pathway in CTCL. The relationship between miRNAs and JAK/ STAT pathway has also recently been elucidated in the pathogenesis of CTCL. For instance, Kopp and coworkers [41] demonstrated that in SzS, IL-2 receptor bc (IL-2Rbc)/ JAK/STAT5 activates miR-155 up-regulation. It is known that IL-2 and IL-15 are ligands of IL-2Rbc. As inhibition of this pathway negatively regulates tumor cell proliferation, this pathway can be said to be oncogenic. However, that group did not show the exact target of miR-155 in SzS. [42] demonstrated that IL-21/JAK/ STAT3 is activated and STAT3 directly regulates a representative oncogenic miRNA, miR-21, in SzS. Narducci and coworkers [38] also reported that miR-21 up-regulation in CTCL has anti-apoptotic function. Qin and coworkers [43] reported up-regulation of miR-199, miR-199*, and miR-214 in the same context. As for miR-199*, Ballabio and coworkers [36] reported the detailed function of miR-199*, finding that miR-199a* combines directly with the promoter region of miR-342, which inhibits transcription of miR-342, leading to anti-apoptotic effects in CTCL cells. Our group recently found a novel target of miR-150, which is a tumor suppressive miRNA in other lymphomas [44] . MiR-150 directly down-regulates C-C chemokine receptor type 6 (CCR6) [45] . It has been suggested that IL-22 and/or chemokine (C-C motif) ligand 20 (CCL20)/ CCR6 interaction may play an important role in the relationship between CTCL and keratinocytes or dendritic cells [46] . We further showed that (1) CTCL cells can produce IL-22 (but not IL-17), and express the IL-22 receptor, whose expression is not found in normal lymphocytes, and that (2) IL-22 stimulation against IL-22RA1 may trigger CCL20 production via activation of JAK/STAT5 pathway, leading to the enhancement of CCL20/CCR6 interaction in advanced CTCL. This interaction may enhance the migration potential of advanced CTCL, resulting in multiple invasion and metastasis of CTCL cells into various visceral organs, following a nutrition-dependent concentration gradient. As CCR6 is strictly controlled by miR-150, down-regulation of miR-150 in CTCL may contribute to the constitutive activation of the IL-22/CCL20/CCR6 autocrine pathway (Fig. 2) . These findings suggest that inhibition of the autocrine pathway may be therapeutically useful in advanced CTCL. Antibody for CCL20 and CCR6 could represent novel molecular targeting therapies against advanced CTCL, as well as ATLL for CCR4 [47] .
Although it is important to distinguish pathological differences between skin invasive lymphomas, Lawrie's group (2012) have shown that miRNA profiling could be useful for diagnosis of C-ALCL from tumor MF or benign inflammatory dermatoses, reporting that miR-155 is highly up-regulated in C-ALCL [48] . This report suggests that miRNA profiling may be useful in distinguishing subtypes, and that information obtained about miRNA and its targets could lead us to develop new therapeutic strategies for ML.
(b) Nodal PTCL (1) ALCL (Fig. 3 ): ALCL is a T-cell lymphoma with CD30 antigen expression. ALCL is a comparatively rare subtype that has been clearly defined as a single tumor entity. ALCL is classified into two subgroups, such as ALK ? and ALK-negative (ALK -) type. The ALK ? type occurs in younger populations than the ALK -type, while the ALK -type occurs more frequently in older patients, and is associated with poorer prognosis [49] . A tyrosine kinase ALK was first identified in ALCL cases with t(2;5)(p23;q35) chromosomal translocation [50] . ALK is located on chromosome 2p23, and nucleophosmin (NPM) is located on chromosome 5q35. This translocation can yield the aberrant chimeric protein NPM-ALK, leading to continuous phosphorylation of ALK, which activates [51] . The role of STAT3 in ALK ? ALCL may in particular be very important in tumorigenesis [52] . Because these downstream activations are known to be enhancers of tumorigenesis, their upstream regulator, ALK, represents a possible therapeutic candidate target [53, 54] .
In ALK ? ALCL, miRNA dysregulation is well documented [55, 56] . Merkel and coworkers [55] ALCL is crucial and essential in the pathogenesis, as STAT3 activates or deactivates transcription and expression of various miRNA gene [64] . STAT3, which is activated by NPM-ALK, epigenetically dysregulates miRNAs, which then contribute to cancer development via alteration of downstream target genes. Recently Miyazono's group (2011) reported the role of miR-135b, which is aberrantly overexpressed in ALK ? ALCL [56, 65] . NPM-ALK activates miR-135b through STAT3 signaling; miR-135b then directly down-regulates forkhead box protein O1 (FOXO1), leading to enhancement of anti-tumor agent resistance. They found that miR-135b contributes to the T H 17 phenotype of ALK ? ALCL, as miR-135b inhibits T H 2 differentiation-related transcription factors, such as STAT6 and GATA3, and up-regulates IL-17A and IL-17F expression in ALK ? ALCL. They further showed that cytokines produced by T H 17 cells contribute to cancer progression via induction of angiogenesis [65] . Spaccarotella and coworkers [63] found that NPM-ALK and up-regulation of STAT3 transcriptionally up-regulate miR-17-92 polycistron, which negatively regulates Bim and TGFb receptor 2, leading to cancer progression in ALK ? ALCL. Zhang and coworkers [66] reported that NPM-ALK/STAT3 signaling inhibits miR-21 transcription and up-regulation of its target, DNA-methyltransferase 1 (DNMT1). Up-regulation of DNMT1 promotes IL-2 receptor common c-chain DNA methylation and thus induces cancer progression by inhibition of T-cell differentiation. They also found that STAT3 down-regulates miR-219 and up-regulates inducible T-cell co-stimulator (ICOS; CD278). ICOS is defined as CD28-costimulatory receptor superfamily, and it contributes to cancer progression by initiating cell activation with TCR-CD3 complex [67] . Zhu and coworkers [68] focused on inducible nitric oxide synthase (iNOS) in the pathogenesis of ALCL. Activated STAT3 by NPM-ALK inhibits miR-26a transcription, leading to iNOS up-regulation. This up-regulation can contribute to tumorigenesis by producing a free-radical NO in the tumor cells. Desjobert and coworkers [69] showed that STAT3 inhibits miR-29a transcription, resulting in MCL1 up-regulation and enhanced anti-apoptotic activity of ALCL. Together, these reports demonstrate that the STAT3 signaling pathway is important, and that its activation contributes to the regulation of several oncomiRs, which themselves contribute to cancer progression in ALK ? ALCL (Fig. 3) . Although downstream miRNA dysregulations of STAT3 are well studied, other ALK-downstream signal pathways, such as AKT, ERK and Ras, have not been reported. Independent of STAT3-related miRNA deregulation, Dejean and coworkers [70] showed angiogenesis-related miRNA; down-regulation of miR-16 activates vascular endothelial growth factor (VEGF), leading to promotion of tumor volumes via vascular endothelial growth.
As mentioned above, while there have been many studies of miRNA function in ALK ? ALCL; there are few such studies in ALK -ALCL. ALK -ALCL thus remains something of a ''waste-box'' disease. Feldman and coworkers [71] showed that relapsed ALK -ALCL recurrently represent t(6;7)(p25.3;q32.3). This translocation activates miR-29a (located in 7q32.3) and down-regulation of the target, DUSP22. Because DUSP22 inhibits the TCR pathway through inactivation of ERK2 and mitogen-activated protein kinase (MAPK) [72] , miR-29a activation may contribute to cancer progression. However, the miR-29 family is also known to include miRNAs that show tumor-suppressive activity in various cancers [73] , making it tempting to speculate that miR-29 may have both oncogenic and tumorsuppressive roles in distinct tumor subtypes.
The recently developed combination of genome-wide gene expression and miRNA expression analyses has further delineated the relationship between miRNA dysregulation and STAT3 signaling. ALK inhibitors such as crizotinib against ALK-positive cancers have been developed [53, 54] , indicating that combination therapies using ALK inhibitors with other molecular targeting agents, including miRNA targets, may be useful in the future. It has been expected to delineate cue signal pathway, which may lead to development of new agents for ALCL therapy through discovery of miRNA-related activated signaling.
(2) ATLL (Fig. 4) : ATLL is defined Human T-lymphotropic Virus-1 (HTLV-1)-infected T-cell malignancy [74] . To better understand the pathogenesis of ATLL, we should pay close attention to the concept of multistage cancer development, and the fact that this lymphoma comprises four or more subgroups, such as acute type, lymphoma type, smoldering type, and chronic types [74] . Because array-based comparative genomic hybridization (CGH) analysis previously showed distinct genomic profiles between acute and lymphoma types [75] , miRNA expression pattern could be distinct in the various ATLL subtypes. Taking into account these problems, in this section we discuss miRNA dysregulation in ATLL. The first report of miRNA expression analysis of HTLV-1 infected T cell was by Bellon and coworkers [76] , who conducted miRNA expression analysis to detect miRNAs associated with the development of HTLV-1 infection. They found that overexpression of miR-155 and miR-142-3p, and down-regulation of miR-125a, miR-132, and miR-181a were commonly observed in both ATLL cell lines and samples.
Recently, in ATLL or other aggressive lymphomas, the importance of the relationship between miRNA and polycomb genes [such as histone-lysine N-methyltransferase 2 (EZH2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI1)] have been reported. In ATLL (acute type), Sasaki and coworkers [77] discovered that overexpression of EZH2 and down-regulation of miR-101 and miR-128a are significantly correlated in ATLL cells derived from peripheral blood samples of ATLL patients. They suggested that activation of EZH2 and related genes might promote tumorigenesis of acute type via down-regulation of miR-101, as EZH2 and Histone H3 trimethyl Lys27 (H3K27me3) are strongly expressed in this lymphoma type as shown by immunohistochemistry assay, and because miR-101 has been demonstrated to directly regulate EZH2 [59] . Watanabe's group (2012) recently demonstrated that miR-31 is significantly down-regulated in ATLL samples (acute type). Polycomb repressive complex 2 (PRC2) (which includes EZH2) is recruited by Yin Yang 1 (YY1) to the promoter region of miR-31. This interaction induces trimethylation and transcriptional inactivation of miR-31 by H3K27me3 activation [78] . They further demonstrated that down-regulation of miR-31 directly up-regulates nuclear factor-kappa B inducing kinase (NIK), leading to activation of the NFjB pathway. This up-regulation could further activate downstream polycomb proteins, and the group suggested that a novel EZH2 inhibitor, GSK126 [79] , might represent a therapeutic candidate against ATLL. Although miRNAs have been shown to play crucial roles in ATLL pathogenesis, especially in that of the acute type, miRNAs specific to ATLL subtypes, such as lymphoma type, have yet to be identified. We previously showed distinct miRNA expression patterns between lymphoma type and leukemia type of NK/T-cell leukemia/ lymphoma [80] , suggesting that essential miRNAs in acute and other types might also be different. Further studies are required to distinguish among acute, lymphoma, chronic, and smoldering ATLL subtypes.
(3) PTCL-NOS: In PTCL-NOS and AITL, the deregulated non-coding RNAs include not only miRNAs (e.g., miR-768-3p), but also small nucleolar RNAs (snoRNAs) (e.g., HBII-239) [81] , although the importance of miRNAs/ snoRNAs in the pathogenesis of PTCL has not been determined. Very recently, Yan and coworkers [82] demonstrated that miR-187 was overexpressed in PTCL-NOS. MiR-187 down-regulated tumor suppressor gene Disabled homolog-2 (DAB2), decreased the interaction of Dab2 with adapter protein Grb2, resulting in Ras activation, phosphorylation/activation of ERK and AKT.
(c) Extranodal PTCL (e.g., ENKL) NK/T-cell lymphoma/leukemia can be classified into leukemic and extra nodal (ENKL) types [83] . We previously showed that up-regulation of miR-21 or miR-155, and down-regulation of miR-150, occur frequently in NK/Tcell leukemia/lymphoma [44, 80] . Briefly, we found that miR-21 is up-regulated in NK-cell leukemia, and miR-155 in ENKL type. These miRNAs, respectively, regulate protein tyrosine phosphatases, Pten or Ship1, whose downregulation commonly activates AKT signaling [80] . Downregulation of miR-150 also contributes to cell proliferation and anti-aging via up-regulation of AKT2 or Dyskerin [44, 83, 84] . A previous review article by our group describes this in greater detail [14] .
Function of dysregulated miRNAs in Myc-expressing malignant lymphomas
Up-regulation of the transcription factor c-Myc is frequently associated with aggressive cancer behavior. Mendell's group has shown c-Myc control transcription of multiple miRNAs [85, 86] . Therefore, the aberrant overexpression or up-regulation of c-Myc may induce aberrant up-or down-regulation of various miRNAs. For instance, c-Myc up-regulates miR-17-92 polycistron and down-regulates the miR-15a/16-1 cluster in cancer [85] [86] [87] . In B-cell lymphoma, c-Myc dysregulation is well known, and recent studies have demonstrated that miRNA dysregulations affected by c-Myc play crucial roles in B-cell lymphomagenesis. Because c-Myc is also overexpressed in aggressive T-cell lymphomas, such as SzS and tumor MF [88] [89] [90] , c-Myc/miRNA dysregulation may also be closely associated with pathogenesis. Below, we describe miRNA dysregulation in c-Myc positive lymphoma. In aggressive B-cell lymphomas with c-Myc overexpression, such as Burkitt's lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma, c-Myc-associated miRNAs play important pathogenetic roles. Zhang and coworkers [91] showed that c-Myc, histone deacetylase 3 (HDAC3) and EZH2 form a repressive complex tethered to miR-29 promoter elements to epigenetically repress miR-29 transcription in c-Myc-expressing lymphoma cells. Downregulation of miR-29 induces up-regulation of cyclindependent kinase 6 (CDK6) and insulin-like growth factor 1 receptor (IGF-1R). c-Myc regulates transcription of miR26a, the down-regulation of which leads to up-regulation of EZH2. This in turn reduces miR-494 expression, leading to up-regulation of c-Myc. This MYC/miR-26a/EZH2/miR-494-positive feedback loop is observed in aggressive B-cell lymphomas. These findings suggest that EZH2 inhibitors may be useful for new molecular targeting therapeutic agents in c-Myc positive B-cell lymphomas. In this manner, researching miRNAs and their targets may lead to the discovery of novel key strategies against MLs, especially aggressive types. Also in T-cell lymphoma, aggressive cases in particular, c-Myc is overexpressed and associated with poor clinical outcome [88] [89] [90] . This suggests that this mechanism may occur commonly between B-and T-cell lymphomas, which show high c-Myc expression. Thus, the same therapeutic strategy may be applicable in c-Mycpositive T-cell lymphoma. Indeed, miR-187 activation could stabilize c-Myc expression in PTCL-NOS and a proteasome inhibitor, bortezomib may be useful in reducing the miR-187/c-Myc axis [83] . Furthermore, it has been recently reported that c-Myc/miR-125b-5p axis determines the sensitivity of bortezomib via modulation of Maxinteracting transcriptional repressor (MAD4) in CTCL [92] . As shown here, functional analysis of proteasome inhibitors against Myc expressing T-cell lymphomas has also been reported, and thus the advanced use of proteasome inhibitors against aggressive T-cell malignancies represents a promising future clinical strategy.
Conclusion
As we hope to have shown in this review, miRNA analysis in T-cell lymphoma/leukemias remains insufficiently understood. Nevertheless, previous reports of deep associations between miRNAs and well-defined T-cell lymphomas strongly suggest that such dysregulation may play crucial roles in undefined T-cell lymphoma subtypes as well. Notably, products that are detected as targets of miRNA may represent therapeutic molecular targets in T-cell lymphoma [e.g., inhibitor of EZH2 methyltransferase activity (GSK126) against ATLL; bortezomib against PTCL-NOS or CTCL]. Further, miRNAs or antisense miRNAs may also represent novel candidate agents for the treatment of cancer, although appropriate delivery systems have yet to be established. As miRNA plays essential roles in normal and cancer cells, we are confident that further studies promise evolutionary approaches to the treatment of aggressive lymphomas.
